Comparing docetaxel with gemcitabine as second-line chemotherapy in patients with advanced non-small cell lung cancer: A single institute randomized phase II study
Journal Title: Journal of Cancer Research & Therapy - Year 2015, Vol 3, Issue 1
Abstract
Background: Platinum-based doublet chemotherapy is the backbone of treatment in advanced non-small cell lung cancer (NSCLC) however second-line treatment options are controversial particularly in patients with borderline performance status (PS) of 2. The aim of this study was to compare efficacy and toxicity of weekly docetaxel versus gemcitabine in this clinical setting. Patients and methods: A total of 70 patients with advanced (stage IIIB, IV) NSCLC entered this single institute study. Cases of this study had experienced disease progression after the first-line platinum-based doublet chemotherapy, with PS 0- 2 in “Eastern Cooperative Oncology Group” scale. They were randomly assigned by stratified blocks to receive docetaxel 35 mg/m2 (Arm A, n=34) or gemcitabine 1000 mg/m2 (Arm B, n=36) days 1, 8 and 15, every three weeks, for up to six cycles. Primary end point was progression free survival (PFS) and secondary end points were objective response rate, disease control rate, median overall survival (OS) and toxicity. Dose modification was permitted upon clinician’s discretion for each individual patient. Results: Median of PFS was 2.02 months in arm A and 2.63 months in arm B (HR= 1.279; 95% CI: 0.710-2.304, P= 0.551). Although median OS for arm A was numerically greater (9.2 months) than arm B (8.3 months) it was statistically non-significant (HR= 1.384; 95% CI: 0.632 to 2.809, P= 0.59). Objective response was higher in Arm B than that in Arm A (P= 0.20) but disease control rates were statistically different in both arms (P= 0.034). Statistically significant differences in term of leukopenia was seen in arm B (P= 0.013). Conclusion: This study, with limited number of cases, indicates that in advanced NSCLC, weekly docetaxel and gemcitabine are reasonable second-line treatment options with statistically similar effectiveness in terms of PFS and median OS with manageable toxicities in patients with PS 0-2.
Authors and Affiliations
Khosravi A, Esfahani-Monfared Z, Karimi SH, Emami H, Khodadad K
Keywords
Related Articles
- EP ID EP544835
- DOI 10.14312/2052-4994.2015-1
- Views 49
- Downloads 0
O-acetylated gangliosides: Structure, biosynthesis, immunogenicity, functions and their potential for cancer immunotherapy
Sialic acid O-acetylation is a developmentally regulated modification of gangliosides implicated in ontogeny and tumor progression. Their existence has been underestimated in the past because of their alkali-labile natur...
The prevention and treatment of peritoneal carcinomatosis from gastric cancer: A 2013 update
Gastric cancer is the fourth most common cancer and the second leading cause of cancer death in the world. Penetration of the gastric serosa and lymphatic spread are the two most important factors affecting prognosis in...
Cancer estimation of incidence and survival in Algeria 2014
Cancer is one of the major public health problems in Algeria. In the last 25 years, a significant increase in the incidence of the major types of cancers has been observed in both sexes. Moreover, the 5-year survival rat...
Primary alveolar rhabdomyosarcoma of breast in a 13 year old female with cardiopulmonary metastases and cyto-histological correlation: A case report
Introduction: Rhabdomyosarcoma is the commonest soft tissue sarcoma of childhood. The tumour commonly occurs in the body regions of the head and neck, genitourinary and extremities. Primary rhabdomyosarcoma of the breast...
Factors associated with refusal of radiotherapy among oral cancer patients
Background: Surgery is commonly favored in the management of oral cancer but radiotherapy may be essential because of the size or location of the tumor. Refusal of radiotherapy by patients is an important issue, which mu...